U.S. Pulmonary Function Testing Systems Market Size, Share & COVID-19 Impact Analysis, By Type (Portable and Complete), By End-user (Hospitals, Physical Examination (Diagnostic) Centers, Physician Groups (Clinics), and Others), and Country Forecast, 2023-2030

The U.S. pulmonary function testing systems market size was worth USD 58.4 million in 2022 and is projected to grow at a CAGR of 4.4% during the forecast period. 

The U.S. has seen a significant rise in the prevalence of asthma and chronic obstructive pulmonary disease, which is anticipated to increase the demand for diagnostic systems and devices in the country. For instance, in 2019, a National Health Survey published by the CDC reported an 8.0% prevalence of asthma in adults aged 18 and above.

Furthermore, the market players are focusing on developing advanced systems and creating awareness of these systems among healthcare facilities. These strategies adopted by market players are anticipated to increase the adoption of these devices in the market.

The influence of COVID-19 resulted in lower demand for pulmonary function testing systems in 2020. The negative impact was due to decreased patient visits for testing pulmonary function and the closure of clinics during the pandemic. However, after the relaxation of the lockdown in the country, the systems resumed in healthcare facilities with the RT-PCR test.

LATEST TRENDS

Transition Toward Portable Systems to Drive Market Growth

In recent years, the market has shifted from complete pulmonary function testing systems to portable systems for diagnosing pulmonary disorders. Factors such as low cost, immobile, and the presence of standard parameters, such as diffusion capacity, lung functioning, and spirometry, stimulated the healthcare facilities to shift towards portable systems.

Furthermore, many market players are developing novel and advanced portable systems to diagnose chronic respiratory disorders.

DRIVING FACTORS

Rising Awareness about Early Diagnosis and Advancements in Pulmonary Function Testing Systems to Drive Market Growth

The increasing prevalence of respiratory diseases, such as chronic obstructive pulmonary disease, lung cancer, and asthma has stimulated the market players, government, and NGOs to create awareness regarding the diagnosis of these diseases. Such awareness helped physicians to provide efficient treatment due to the early diagnosis of pulmonary diseases.

Furthermore, the various campaigns conducted by the organizations to demonstrate the efficacy of the pulmonary function tests are expected to support the U.S. pulmonary function testing systems market growth.

• For instance, a study published by the American Journal of Managed Care (AJMC) in May 2021 concluded that physicians should examine patients with pulmonary function tests to diagnose chronic obstructive pulmonary disease. Such studies favor using innovative systems for pulmonary testing, thereby increasing their adoption during the forecast period.

In the U.S., there was an increase in the prevalence of asthma by 4.4%. The prevalence of asthma was 24.9 million in 2021 and increased to around 26.0 million in 2022 in the U.S.

RESTRAINING FACTORS

Risk of Cross-Contamination to Limit the Market Growth

The pulmonary function testing systems include rebreathing valves, mouthpieces, and tubings used in the laboratory. These parts of the systems are the typical cause of cross-infection in pulmonary function testing. Healthcare facilities are increasingly focused on patient safety and infection control, especially after the outbreak of COVID-19. The fear of cross-contamination during the examination is expected to limit the adoption of these systems among healthcare facilities, thereby hampering market growth.

SEGMENTATION

By Type Analysis

Based on type, the U.S. market is bifurcated into portable and complete.

The portable segment is anticipated to grow at the highest CAGR during the forecast period due to its portability and comparatively low cost than complete systems, making them a preferred option, especially in independent physician clinics. Additionally, the shift toward portable PFT systems among physicians is the primary factor driving the segment's growth.

By End User Analysis

Based on end-user, the U.S. market is segmented into hospitals, physical examination (diagnostic) centers, physician groups (clinics), and others.

The physician groups (clinics) segment is expected to grow at the highest CAGR during the forecast period. The growth is attributed to the rising patient population for pulmonary function testing and the growing number of patient visits to clinics to examine lung-related diseases.

• For instance, according to the article published by Jobson Medical Information LLC in July 2021, 5.7 million were diagnosed with chronic obstructive pulmonary disease during a physician's office visit in the U.S.

KEY INDUSTRY PLAYERS

In terms of the competitive landscape, the market is consolidated, attributed to the large U.S. pulmonary function testing systems market share held by two major companies, namely VYAIRE MEDICAL, INC., and MGC Diagnostics Corporation. The prominent presence of MGC Diagnostics Corporation in the market is due to its strong product portfolio of pulmonary function testing systems and growing focus on the approvals to launch advanced devices in the market.

Some other companies with a considerable presence in the market include KoKo PFT, ndd Medizintechnik AG, COSMED srl, and other small and medium-sized market players. These companies are focusing on strategic moves, such as launching advanced systems to strengthen their product portfolio, which is expected to attract more market share.

LIST OF KEY COMPANIES PROFILED:

• ndd Medizintechnik AG (Switzerland)


• COSMED srl (Italy)


• MGC Diagnostics Corporation (U.S.)


• PulmOne Advanced Medical Devices (Israel)


• VYAIRE MEDICAL, INC. (U.S.)


• KoKo PFT (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• June 2021 - KoKo PFT announced a joint manufacturing partnership with EirMed. The association is for the manufacturing of respiratory medical devices.


• June 2021 - PulmOne Advanced Medical Devices opened a new office in the Texas, U.S. to expand its presence in the U.S. market


• August 2019 - VYAIRE MEDICAL, INC received the FDA 510(k) clearance by the U.S. FDA for two of its latest Pulmonary Function Testing (PFT) technologies, which are Vyntus ONE and Vyntus BODY with SentrySuite Software.

REPORT COVERAGE

The U.S. pulmonary function testing systems market report provides a detailed analysis of the market. It focuses on technological advancements of the device, key industry developments, such as mergers and acquisitions. Additionally, it includes regulatory policies regarding the prevalence of chronic obstructive pulmonary disease and asthma. Besides this, the report also offers insights into industry trends and COVID-19 on the market.

Report Scope & Segmentation